Comparative pharmacology of josamycin and erythromycin stearate. 1976

L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande

Two macrolide antibiotics, josamycin and erythromycin stearate, were administered orally to healthy, adult male volunteers for a comparative study of their pharmacological properties. In comparable doses, josamycin and erythromycin produced similar plasma concentrations, with similar half-lives and elimination constants. An initial loading dose of 1.5 g of josamycin produced greater peak concentrations of antibiotic throughout a 10-day period with a regimen of every 6 h. In addition, josamycin tended to reach higher peak and trough concentrations after regimens of every 6 or 8 h were maintained for 2 days. Josamycin penetrated into saliva, sweat, and tears, and it was better tolerated in fasting subjects than was erythromycin stearate.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007933 Leucomycins An antibiotic complex produced by Streptomyces kitasatoensis. The complex consists of a mixture of at least eight biologically active components, A1 and A3 to A9. Leucomycins have both antibacterial and antimycoplasmal activities.
D008297 Male Males
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
February 1960, Antibiotic medicine & clinical therapy (New York, NY),
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
August 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
September 1953, Antibiotics & chemotherapy (Northfield, Ill.),
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
September 1989, The Journal of pharmacology and experimental therapeutics,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
September 1988, International journal of clinical pharmacology, therapy, and toxicology,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
June 1980, MMW, Munchener medizinische Wochenschrift,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
June 1954, Journal of the American Medical Association,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
January 1969, The Journal of the Egyptian Medical Association,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
January 1963, Bulletin de la Societe francaise de dermatologie et de syphiligraphie,
L J Strausbaugh, and W K Bolton, and J A Dilworth, and R L Guerrant, and M A Sande
May 1971, The Medical journal of Australia,
Copied contents to your clipboard!